Drugs / LIV-GAMMA SN Inj.
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05666453 | Apr 2022 → May 2024 | — | SK Plasma Co., Ltd. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03164915 | Oct 2016 → Apr 2018 | autoimmune thrombocytopenia | SK Plasma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIV-GAMMA SN Inj. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03164915 ↗ |
| Modality | Protein / enzyme biologic | “Intravenous Immunoglobulin to Prevent Biliary Complications” NCT05666453 ↗ |
| Route | Intravenous | “Intravenous Immunoglobulin to Prevent Biliary Complications After ABO Incompatible Adult to Adult Living Donor Liver Transplantation” NCT05666453 ↗ |